{
  "PartitionKey": "ACSFT210719992",
  "RowKey": "EUROPATH_INAS_20201013",
  "Timestamp": "10/13/2020 6:25:36 PM",
  "Program": "EUROPATH",
  "Staff": "glenda.mccarthy",
  "Status": "Complete",
  "SurveyData": {
    "Gender": "female",
    "IndigenousStatus": "aboriginal but not tsi",
    "PreferredLanguage": "english",
    "CountryOfBirth": "kenya",
    "ClientType": "item2",
    "SourceOfReferral": "aod",
    "PrincipalDrugOfConcern": "cocaine",
    "how_many_days": "20",
    "MethodOfUse": "inhales",
    "CreatedDatetime": "10/13/2020 6:16:33 PM",
    "AODHistory": [
      {
        "drug_type": "cannabinoids",
        "age_first_used": 9,
        "how_often_used": "weekly",
        "method_of_use": "transdermal",
        "usage_units": "shots",
        "units_consumed_per_period": "40 - 49"
      }
    ],
    "clientID": "5675",
    "OtherDrugsOfConcern": [
      {
        "drug_type": "cannabinoid",
        "method_of_use": "injects",
        "how_many_days": "22"
      }
    ],
    "aod_harms_risks": ["memloss"],
    "impctdaily": "3",
    "additive_behaviours": ["sex", "other"],
    "additive_behaviours-Comment": "These are other additive behaviours"
  },
  "SurveyID": "ddc3dec4-6de5-4bc9-a963-87e20896feed",
  "SurveyName": "ANSA InitialAssessment"
}
